echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Jianyou shares bensulfosan atracurium injection obtained notice of clinical trial

    Jianyou shares bensulfosan atracurium injection obtained notice of clinical trial

    • Last Update: 2020-01-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 6, Jianyou Co., Ltd announced that the company had recently received the notice of clinical trial approved and issued by the State Food and drug administration, and the drug involved was bensulfonaatracurium injection , Bensulfosan atracurium injection, developed by Aspen / GSK, was purchased by glaxowellcome and approved by FDA in December 1995 The product name is nimbex and the dosage form is injection Abbott obtained the right to operate glaxowellcome narcotic drugs in the U.S market in November 1999, so it is now listed in the U.S by Abbott In January 1996, nimbex was first approved for listing in Denmark Cisatracurium besylate injection is a kind of muscle relaxant, which can be metabolized through non liver and non kidney pathway The effect of muscle relaxant is three times stronger than that of atracurium besylate.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.